Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Oncology
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Metastatic Hormonesensitive Prostate Cancer (mHSPC)?
There are 1 clinical trial targeting Metastatic Hormonesensitive Prostate Cancer (mHSPC) tracked by BioSniper.
What is the prevalence of Metastatic Hormonesensitive Prostate Cancer (mHSPC)?
The estimated prevalence of Metastatic Hormonesensitive Prostate Cancer (mHSPC) is approximately 256.0 per 100,000 population.
Deep-dive into Metastatic Hormonesensitive Prostate Cancer (mHSPC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis